Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation

Swati Rao, Mythili Ghanta, Iris J. Lee, Avrum Gillespie, Hemant K. Parekh, Steven S. Geier, Xu Zeng, Andreas Karachristos, Kwan N. Lau, Sunil Karhadkar, Antonio Di Carlo, Nicole M. Sifontis, Serban Constantinescu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Kidney transplantation (KT) recipients with donor specific HLA antibodies (DSA) encounter higher rates of acute rejection and inferior allograft survival. We report our single center experience with prospective DSA monitoring and provide details of treatments utilized to overcome the potential impact of DSA in a cohort of predominantly African American adult KT recipients. Seventy-five flow crossmatch negative KT recipients underwent periodic screening for DSA utilizing the single antigen bead assay at 3, 6, 9, and 12 months post-transplant. Allograft biopsies were performed in the presence of DSA and/or evidence of graft dysfunction. The incidence of DSA was 23%, with a predominance of Class II antibodies. The rate of rejection was 6 times higher in DSA positive KT recipients compared to DSA negative patients (41% versus 7%, p = 0.004). In the DSA positive group, rejections occurred exclusively in the presence of de novo DSA and were predominantly antibody-mediated or mixed rejections. Despite a higher incidence of rejection in KT recipients with DSA, there were no significant differences in serum creatinine, graft survival, and patient survival between DSA positive and negative recipients at median follow-up of 18 months. DSA positive patients had significantly higher proteinuria compared to DSA negative recipients at 6 months, 1 year, and 3 years of follow-up. In conclusion, the detrimental effects of DSA on allograft function could be mitigated by serial DSA surveillance, protocol biopsies, and alterations in immunosuppression. With these measures, the improvement in graft survival in DSA positive KT recipients, at least at short-term, is encouraging.

Original languageEnglish (US)
Pages (from-to)143-151
Number of pages9
JournalClinical transplants
StatePublished - Jan 1 2014

Fingerprint

Kidney Transplantation
Tissue Donors
Antibodies
Allografts
Graft Survival
Transplants
Biopsy
Donor Selection
Immunoglobulin Isotypes
Incidence
Proteinuria
African Americans
Immunosuppression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rao, S., Ghanta, M., Lee, I. J., Gillespie, A., Parekh, H. K., Geier, S. S., ... Constantinescu, S. (2014). Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation. Clinical transplants, 143-151.

Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation. / Rao, Swati; Ghanta, Mythili; Lee, Iris J.; Gillespie, Avrum; Parekh, Hemant K.; Geier, Steven S.; Zeng, Xu; Karachristos, Andreas; Lau, Kwan N.; Karhadkar, Sunil; Di Carlo, Antonio; Sifontis, Nicole M.; Constantinescu, Serban.

In: Clinical transplants, 01.01.2014, p. 143-151.

Research output: Contribution to journalArticle

Rao, S, Ghanta, M, Lee, IJ, Gillespie, A, Parekh, HK, Geier, SS, Zeng, X, Karachristos, A, Lau, KN, Karhadkar, S, Di Carlo, A, Sifontis, NM & Constantinescu, S 2014, 'Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation', Clinical transplants, pp. 143-151.
Rao S, Ghanta M, Lee IJ, Gillespie A, Parekh HK, Geier SS et al. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation. Clinical transplants. 2014 Jan 1;143-151.
Rao, Swati ; Ghanta, Mythili ; Lee, Iris J. ; Gillespie, Avrum ; Parekh, Hemant K. ; Geier, Steven S. ; Zeng, Xu ; Karachristos, Andreas ; Lau, Kwan N. ; Karhadkar, Sunil ; Di Carlo, Antonio ; Sifontis, Nicole M. ; Constantinescu, Serban. / Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation. In: Clinical transplants. 2014 ; pp. 143-151.
@article{bf0c4243ffd2453eb4927752505b45e9,
title = "Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation",
abstract = "Kidney transplantation (KT) recipients with donor specific HLA antibodies (DSA) encounter higher rates of acute rejection and inferior allograft survival. We report our single center experience with prospective DSA monitoring and provide details of treatments utilized to overcome the potential impact of DSA in a cohort of predominantly African American adult KT recipients. Seventy-five flow crossmatch negative KT recipients underwent periodic screening for DSA utilizing the single antigen bead assay at 3, 6, 9, and 12 months post-transplant. Allograft biopsies were performed in the presence of DSA and/or evidence of graft dysfunction. The incidence of DSA was 23{\%}, with a predominance of Class II antibodies. The rate of rejection was 6 times higher in DSA positive KT recipients compared to DSA negative patients (41{\%} versus 7{\%}, p = 0.004). In the DSA positive group, rejections occurred exclusively in the presence of de novo DSA and were predominantly antibody-mediated or mixed rejections. Despite a higher incidence of rejection in KT recipients with DSA, there were no significant differences in serum creatinine, graft survival, and patient survival between DSA positive and negative recipients at median follow-up of 18 months. DSA positive patients had significantly higher proteinuria compared to DSA negative recipients at 6 months, 1 year, and 3 years of follow-up. In conclusion, the detrimental effects of DSA on allograft function could be mitigated by serial DSA surveillance, protocol biopsies, and alterations in immunosuppression. With these measures, the improvement in graft survival in DSA positive KT recipients, at least at short-term, is encouraging.",
author = "Swati Rao and Mythili Ghanta and Lee, {Iris J.} and Avrum Gillespie and Parekh, {Hemant K.} and Geier, {Steven S.} and Xu Zeng and Andreas Karachristos and Lau, {Kwan N.} and Sunil Karhadkar and {Di Carlo}, Antonio and Sifontis, {Nicole M.} and Serban Constantinescu",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
pages = "143--151",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation

AU - Rao, Swati

AU - Ghanta, Mythili

AU - Lee, Iris J.

AU - Gillespie, Avrum

AU - Parekh, Hemant K.

AU - Geier, Steven S.

AU - Zeng, Xu

AU - Karachristos, Andreas

AU - Lau, Kwan N.

AU - Karhadkar, Sunil

AU - Di Carlo, Antonio

AU - Sifontis, Nicole M.

AU - Constantinescu, Serban

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Kidney transplantation (KT) recipients with donor specific HLA antibodies (DSA) encounter higher rates of acute rejection and inferior allograft survival. We report our single center experience with prospective DSA monitoring and provide details of treatments utilized to overcome the potential impact of DSA in a cohort of predominantly African American adult KT recipients. Seventy-five flow crossmatch negative KT recipients underwent periodic screening for DSA utilizing the single antigen bead assay at 3, 6, 9, and 12 months post-transplant. Allograft biopsies were performed in the presence of DSA and/or evidence of graft dysfunction. The incidence of DSA was 23%, with a predominance of Class II antibodies. The rate of rejection was 6 times higher in DSA positive KT recipients compared to DSA negative patients (41% versus 7%, p = 0.004). In the DSA positive group, rejections occurred exclusively in the presence of de novo DSA and were predominantly antibody-mediated or mixed rejections. Despite a higher incidence of rejection in KT recipients with DSA, there were no significant differences in serum creatinine, graft survival, and patient survival between DSA positive and negative recipients at median follow-up of 18 months. DSA positive patients had significantly higher proteinuria compared to DSA negative recipients at 6 months, 1 year, and 3 years of follow-up. In conclusion, the detrimental effects of DSA on allograft function could be mitigated by serial DSA surveillance, protocol biopsies, and alterations in immunosuppression. With these measures, the improvement in graft survival in DSA positive KT recipients, at least at short-term, is encouraging.

AB - Kidney transplantation (KT) recipients with donor specific HLA antibodies (DSA) encounter higher rates of acute rejection and inferior allograft survival. We report our single center experience with prospective DSA monitoring and provide details of treatments utilized to overcome the potential impact of DSA in a cohort of predominantly African American adult KT recipients. Seventy-five flow crossmatch negative KT recipients underwent periodic screening for DSA utilizing the single antigen bead assay at 3, 6, 9, and 12 months post-transplant. Allograft biopsies were performed in the presence of DSA and/or evidence of graft dysfunction. The incidence of DSA was 23%, with a predominance of Class II antibodies. The rate of rejection was 6 times higher in DSA positive KT recipients compared to DSA negative patients (41% versus 7%, p = 0.004). In the DSA positive group, rejections occurred exclusively in the presence of de novo DSA and were predominantly antibody-mediated or mixed rejections. Despite a higher incidence of rejection in KT recipients with DSA, there were no significant differences in serum creatinine, graft survival, and patient survival between DSA positive and negative recipients at median follow-up of 18 months. DSA positive patients had significantly higher proteinuria compared to DSA negative recipients at 6 months, 1 year, and 3 years of follow-up. In conclusion, the detrimental effects of DSA on allograft function could be mitigated by serial DSA surveillance, protocol biopsies, and alterations in immunosuppression. With these measures, the improvement in graft survival in DSA positive KT recipients, at least at short-term, is encouraging.

UR - http://www.scopus.com/inward/record.url?scp=84940972214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940972214&partnerID=8YFLogxK

M3 - Article

C2 - 26281139

AN - SCOPUS:84940972214

SP - 143

EP - 151

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -